AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05050084
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05050084
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection
Trial: NCT05050084
Drug: Flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05050084
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT05050084
Drug: Histrelin
RxNorm normalized name: Histrelin
DrugBank: Histrelin (DB06788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant
Trial: NCT05050084
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT05050084
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT05050084
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT06597201
Drug: amino acid (15) peritoneal dialysis solution
RxNorm normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were treated with 1 bag of amino acid (15) peritoneal dialysis solution (2L) once every morning, and then with conventional glucose peritoneal dialysate (lactate).
Trial: NCT06617923
Drug: Senaparib
RxNorm normalized name: Senaparib
DrugBank: Senaparib (DB17163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
Trial: NCT06617923
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
Trial: NCT06743581
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg administered intravenously on day 1
Trial: NCT06743581
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab 600 mg administered subcutaneously on day 1
Trial: NCT05338632
Drug: Naloxone Hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone 0.4mg/mL
Trial: NCT05338632
Drug: Nalmefene HCl injection
RxNorm normalized name: nalmefene Injection
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nalmefene 1 ng/mL
Trial: NCT06763731
Drug: Systane COMPLETE
RxNorm normalized name: Systane Complete Preservative Free
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preop dry eye management using Systane COMPLETE can help to optimize the ocular surface.
Trial: NCT06758882
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administration of non steroid androgenic receptor inhibitors plus androgen deprivation therapy
Trial: NCT06762041
Drug: Metformin treatment
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interested subjects with autism are treated with metformin with a standard dosage
Trial: NCT06759558
Drug: Zuranolone
RxNorm normalized name: Zuranolone
DrugBank: Zuranolone (DB15490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuranolone is a neuroactive steroid that works by modulating the activity of the gamma-aminobutyric acid (GABA) receptor in the brain.
Trial: NCT06746701
Drug: Peg-IFNα-2b combined with NA
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.
Trial: NCT06758739
Drug: Intralesional Steroid Injection
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.
Trial: NCT06759636
Drug: Romiplostim N01
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10\^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10\^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.
Trial: NCT06759636
Drug: Recombinant Human Interleukin-11 (rhIL-11)
RxNorm normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-50μg/kg, subcutaneous injection, once a day
Trial: NCT06747936
Drug: AD-2281
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06747936
Drug: AD-2282
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, Once daily, 8weeks
Trial: NCT06740370
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Trial: NCT06740370
Drug: PD-1 Inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
Trial: NCT05681442
Drug: AG infusion most 1 dose
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG infusion most 1 dose (AMT group )
Trial: NCT06762600
Drug: HRS-4729 injection
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-4729 injection
Trial: NCT06772779
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT06772779
Drug: Enlicitide Decanoate
RxNorm normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT06772779
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT06752590
Drug: ONO-1110
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-1110 tablets once a day
Trial: NCT06754059
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, after at least 4 cycles of taxoid chemotherapy combined with trastuzumab ± pertuzumab, the evaluation result reached SD, CR or PR, and capecitabine combined with pyrotinib + trastuzumab was given successively in the later period (capecitabine was used for 4-6 cycles
Trial: NCT06763159
Drug: HS-20124 (Phase Ia：Dose escalation )
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Trial: NCT06763159
Drug: HS-20124 (Phase Ib: Dose expansion)
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Trial: NCT06765109
Drug: Neladalkib (NVL-655)
RxNorm normalized name: NVL-655
DrugBank: NVL-655 (DB18682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet of Neladalkib (NVL-655)
Trial: NCT06765109
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral capsule of alectinib
Trial: NCT06767085
Drug: Lidocaine-Prilocaine Topical
RxNorm normalized name: lidocaine-prilocaine topical
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine-prilocaine spray on the cervix and cervical canal 5-7 minutes prior to the procedure
Trial: NCT05268237
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sublingual or subcutaneous liraglutide
Trial: NCT06763315
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of the internationally recommended standard dose and low dose of the same drug
Trial: NCT06740188
Drug: Citalopram hydrobromide combined with zolpidem
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the control group was given citalopram hydrobromide combined with zolpidem
Trial: NCT06191315
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Trial: NCT06754098
Drug: Doxecitine and Doxribtimine
RxNorm normalized name: Doxecitine
DrugBank: 2'-Deoxycytidine (DB02594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
Trial: NCT06516887
Drug: bemcentinib
RxNorm normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
Trial: NCT06516887
Drug: pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
Trial: NCT06372145
Drug: Tolebrutinib
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Trial: NCT06372145
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Trial: NCT05973851
Drug: Esketamine Nasal Product
RxNorm normalized name: esketamine Nasal Product
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT05973851
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT05973851
Drug: Esketamine hydrochloride
RxNorm normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: See arm description
Trial: NCT05662397
Drug: HST-1011
DrugBank: ST-101 (DB12621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HST-1011 given orally
Trial: NCT06752798
Drug: Trilaciclib + Cisplatin
RxNorm normalized name: Trilaciclib
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilaciclib: 240 mg/m², intravenous infusion over 30 minutes, administered within 4 hours prior to each chemotherapy session. Cisplatin: 40 mg/m², intravenous infusion over 2-3 hours, once a week, for a total of 6-7 times.
Trial: NCT06311578
Drug: JNJ-87704916
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-87704916 will be administered as an intratumoral injection.
Trial: NCT06311578
Drug: Cetrelimab
RxNorm normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrelimab will be administered.
Trial: NCT06747728
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
Trial: NCT04802161
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04802161
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06785298
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
Trial: NCT06761417
Drug: Mitoxantrone liposome
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.
Trial: NCT06761417
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients \> 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.
Trial: NCT06765928
Drug: selinexor in combination with venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After allo-HSCT, intermediate-high risk MDS/AML patients are maintenanced with selinexor given in combination with venetoclax for 2 years
Trial: NCT06749691
Drug: Liposomal Irinotecan and Apatinib
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Liposomal Irinotecan in Combination With Apatinib
Trial: NCT06754267
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BCL-2 inhibotor
Trial: NCT06754267
Drug: Olverembatinib
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor
Trial: NCT06754267
Drug: Predinisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticoids
Trial: NCT06767527
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 via intravenous (IV) infusion
Trial: NCT06767527
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
Trial: NCT05468320
Drug: Caplacizumab
RxNorm normalized name: caplacizumab
DrugBank: Caplacizumab (DB06081)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lyophilized powder for solution for injection.
Trial: NCT06758544
Drug: Oncolytic virus VRT106
RxNorm normalized name: rubella virus
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRT106, IV
Trial: NCT06769828
Drug: Ga-68-FAPI-46
RxNorm normalized name: Fapilavir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Ga-68-FAPI-46 PET scan in colorectal cancer
Trial: NCT06769698
Drug: FDC fianlimab+cemiplimab
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-Dose Combination (FDC) Administered per the protocol
Trial: NCT06769698
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered per the protocol
Trial: NCT06762587
Drug: Baloxavir Marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baloxavir marboxil will be administered on the first day following the close contact's enrollment in this study. Participants weighing ≤80 kg will receive 40 mg of baloxavir marboxil, while those weighing ≥80 kg will receive 80 mg.
Trial: NCT06762587
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir will be administered once daily for 5 consecutive days following the close contact's enrollment in this study. Participants will receive 75 mg of oseltamivir once each day.
Trial: NCT05709574
Drug: Tadalafil 20 MG
RxNorm normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
Trial: NCT06388083
Drug: Tinlarebant
RxNorm normalized name: Tinlarebant
DrugBank: Tinlarebant (DB17832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tablet
Trial: NCT06609928
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06775275
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab
Trial: NCT06775275
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.
Trial: NCT06777732
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT06777732
Drug: Furazolidone
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT06777732
Drug: Colloidal Bismuth Pectin
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric mucosal protectant
Trial: NCT06770465
Drug: Different categories of antibiotics
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
Trial: NCT06775392
Drug: bromelain-quercetin gel
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromelain-quercetin gel is prepared from capsules in laboratory
Trial: NCT06775392
Drug: chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chlorhexidine gel is prepared in laboratory
Trial: NCT06765954
Drug: N-803 (IL-15 Superagonist)
RxNorm normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC) both before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
Trial: NCT06765954
Drug: ETBX-071 (PSA-based Oncolytic Virus)
RxNorm normalized name: rubella virus
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC) before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
Trial: NCT05501548
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300mg by mouth twice daily